company background image
GNTA

Genenta Science NasdaqCM:GNTA Stock Report

Last Price

US$6.30

Market Cap

US$114.8m

7D

-0.2%

1Y

n/a

Updated

12 Aug, 2022

Data

Company Financials +
GNTA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

GNTA Stock Overview

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy.

Genenta Science S.p.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Genenta Science
Historical stock prices
Current Share PriceUS$6.30
52 Week HighUS$13.13
52 Week LowUS$5.11
Beta0
1 Month Change-2.33%
3 Month Change5.35%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-42.73%

Recent News & Updates

Jul 25

Gene therapy developer Genenta Science named a buy at Wainwright on tumor approach

H.C. Wainwright has initiated stem cell gene therapy developer Genenta Science (NASDAQ:GNTA) as a buy seeing promise for the company's technology providing advantages differentiating elements over other cellular therapies for cancer. The firm has a $25 price target (269% upside based on Friday's close). Genenta shares are down 9% in early Monday afternoon tradig. Analyst Emanuela Branchetti said that the company's technology is "based on the ex-vivo lentiviral vector (LVV) mediated modification of autologous hematopoietic stem/progenitor cells (HSPCs) that deliver immunomodulatory molecules directly to the tumor." She highlighted four advantages/differentiating factors of Genenta's (GNTA) tech: 1. It focuses on a type tumor-associated myeloid cells (TEMs) that known to be involved in promoting angiogenesis and tumor growth; 2. It is built in a way that controls transgene expression and avoids off-target and systemic toxicity; 3. It has potential for long-tern durabiklity given the use of HSPCs; and 4) It is agnostic so it could potentially be used in a wide variety of cancers. Genenta's (GNTA) lead candidate, temferon, is currently in phase 1/2a for glioblastoma multiforme. It is idesigned to deliver IFN-α only at the tumor site. A data update is expected in this half of the year with enrollment completion in H1 2023. A phase 2 study is planned for H2 2023.

Mar 18
Is Genenta Science (NASDAQ:GNTA) In A Good Position To Invest In Growth?

Is Genenta Science (NASDAQ:GNTA) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

GNTAUS BiotechsUS Market
7D-0.2%1.2%3.2%
1Yn/a-21.7%-10.1%

Return vs Industry: Insufficient data to determine how GNTA performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how GNTA performed against the US Market.

Price Volatility

Is GNTA's price volatile compared to industry and market?
GNTA volatility
GNTA Average Weekly Movement10.0%
Biotechs Industry Average Movement12.5%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: GNTA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: GNTA's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20144Pierluigi Paracchihttps://www.genenta.com

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company’s lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma.

Genenta Science S.p.A. Fundamentals Summary

How do Genenta Science's earnings and revenue compare to its market cap?
GNTA fundamental statistics
Market Cap€111.93m
Earnings (TTM)-€5.53m
Revenue (TTM)n/a

0.0x

P/S Ratio

-20.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GNTA income statement (TTM)
Revenue€0
Cost of Revenue€0
Gross Profit€0
Other Expenses€5.53m
Earnings-€5.53m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.30
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did GNTA perform over the long term?

See historical performance and comparison